Oxygen Therapy, Hyperbaric Oxygen Therapy, or Mild Hyperbaric Exposure: What Is the Difference?

In summary

The word “oxygen” creates the impression that all technologies designed to increase its availability essentially do the same thing. They do not. Breathing supplemental oxygen at normal atmospheric pressure, breathing a high concentration of oxygen under substantially elevated pressure during medical hyperbaric oxygen therapy, and being exposed to a mildly pressurized chamber while breathing a lower concentration of O₂ represent physically and biologically different exposures.

In normobaric oxygen therapy, the primary variable that changes is the concentration of oxygen in the inspired gas mixture — FiO₂ — while ambient pressure remains approximately 1 atmosphere absolute, or 1 ATA. In hyperbaric oxygen therapy, two variables change simultaneously: the person breathes a high, typically near-100% concentration of medical oxygen while also being exposed to increased absolute ambient pressure. In mild hyperbaric exposure, pressure is increased to a lesser degree, while the concentration of O₂ actually inhaled may be substantially lower or may depend on the specific delivery system. Contemporary scientific literature therefore explicitly warns that traditional medical HBOT and mild hyperbaric exposure are not synonymous.

The difference is not merely terminological. It determines oxygen partial pressure, the amount of O₂ physically dissolved in plasma, the magnitude of hyperoxic exposure, the effects of pressure itself, the safety profile, and the quality of clinical evidence that can legitimately be associated with a given exposure.

For this reason, TANVEA will not use outcomes from medical HBOT as automatic evidence for the effects of mild hyperbaric wellness exposure. If a study used nearly 100% medical oxygen at 2.0–2.5 ATA, its result belongs to that specific exposure. A pressure of 1.3 or 1.5 ATA, a different FiO₂, a different breathing interface, and a different exposure time create a different dose.

“Oxygen therapy” is a broader term than it may first appear

In medicine, oxygen therapy most commonly refers to the administration of supplemental oxygen to a patient in order to correct or prevent hypoxemia or to achieve a specific clinical objective. Oxygen may be delivered through a nasal cannula, mask, high-flow system, or another interface while the patient remains at normal atmospheric pressure.

This is normobaric oxygen therapy.

It is important to understand that modern medicine does not treat oxygen as a universally beneficial substance that should be given according to the principle “the more, the better.” Clinical guidelines work with target ranges of oxygenation and controlled administration; excessive oxygenation does not necessarily provide additional benefit and may, under certain circumstances, be undesirable. This is why modern respiratory guidance emphasizes titrating oxygen according to the clinical situation rather than indiscriminately administering high concentrations to every patient.

This is the first important boundary:

oxygen therapy is not synonymous with hyperbaric oxygen therapy.

With normobaric O₂, the primary variable we change is FiO₂. Ambient pressure remains approximately 1 ATA.

Hyperbaric oxygen therapy changes both oxygen concentration and pressure

During medical hyperbaric oxygen therapy — HBOT — a person is placed inside a pressure chamber while breathing medical oxygen at a very high concentration.

Definitions have varied slightly over the decades and between professional organizations. Older scientific definitions used approximately 1.4 ATA while breathing nearly 100% O₂ as a lower boundary for clinically relevant hyperbaric oxygen exposure. More recent clinical frameworks are considerably stricter and describe clinical HBO₂ as a physician-prescribed and professionally supervised procedure performed in a pressure vessel that meets relevant safety standards, at pressures of at least approximately 2.0 ATA while breathing medical oxygen, typically for about 90–120 minutes. Evidence-supported clinical protocols are commonly used in a range of roughly 1.9 to 3.0 ATA.

TANVEA will therefore use the term medical HBOT for the clinical hyperbaric context, not for every exposure inside a chamber at a pressure above atmospheric pressure.

This distinction is not semantic nitpicking. If a person breathes 100% O₂ at 2 ATA, the physical conditions of their oxygen exposure are dramatically different from those of a person breathing ordinary air at 1.3 ATA.

Mild hyperbaric exposure is a third, separate category

The term mild hyperbaric oxygen therapy — mHBOT is frequently used commercially. The problem is that very different exposures may be placed under this single label.

Current literature typically describes mild hyperbaric exposure as an environment below approximately 1.5 ATA, often around 1.2–1.5 ATA, while the concentration of inhaled oxygen may be substantially lower than in conventional medical HBOT. Contemporary reviews explicitly separate traditional HBOT from mild hyperbaric oxygenation and emphasize that their physiology, clinical applications, and quality of evidence are different.

Professional hyperbaric frameworks go even further and do not consider low-pressure exposures below approximately 1.5 ATA automatically equivalent to medical HBOT or automatically supported by the same clinical indications.

For TANVEA, it is therefore more accurate to speak of:

mild hyperbaric exposure

rather than automatically using the term:

mild hyperbaric therapy.

The word exposure accurately describes what is physically happening — a person is exposed to mildly elevated pressure and, depending on the configuration, potentially to an elevated oxygen partial pressure — without automatically implying treatment of a specific disease.

Three similar-sounding terms, three different exposures

	Normobaric oxygen therapy	Medical HBOT	Mild hyperbaric exposure
Ambient pressure	approximately 1 ATA	typically approximately 2–3 ATA	typically approximately 1.2–1.5 ATA
FiO₂	higher than room air depending on the system	usually nearly 100% medical O₂	depends on the device and delivery method
What primarily changes	FiO₂	FiO₂ + pressure	primarily pressure, potentially also FiO₂
Dissolved O₂ in plasma	increases	increases substantially	change depends on pressure and actual FiO₂
Typical context	medical oxygen therapy	medical hyperbaric treatment	low-pressure exposure / wellness or research context
Can evidence from clinical HBOT be transferred?	not automatically	own clinical protocols	no

The boundaries between these terms are not defined identically in every country or publication. This is precisely why TANVEA considers it more important to specify the actual pressure, actual FiO₂, delivery method, and exposure time than to rely on the commercial name of a procedure.

Oxygen partial pressure matters more than the percentage shown on a display

One of the most common misunderstandings surrounding oxygen technologies is the assumption that oxygen concentration alone describes the dose.

It does not.

As a first-order physical approximation, the partial pressure of oxygen in a dry inspired gas mixture can be expressed as:

PO₂ ≈ FiO₂ × absolute ambient pressure.

If we breathe air containing approximately 21% O₂ at 1 ATA, the approximate oxygen partial pressure in the dry inspired mixture is about 0.21 ATA. With the same air at 1.3 ATA, it rises to approximately 0.273 ATA. At 1.5 ATA, it rises to approximately 0.315 ATA.

That is a real change.

It is, however, very different from breathing nearly 100% oxygen at 2 ATA, where the theoretical O₂ partial pressure in the dry inspired gas approaches 2 ATA. Actual alveolar and arterial PO₂ are lower because water vapor, CO₂, ventilation, ventilation–perfusion relationships, and lung function all influence the final value, but the underlying physical principle remains the same. Hyperbaric conditions combined with high FiO₂ therefore create a much greater oxygen exposure than mild pressure elevation while breathing air.

This is one of the reasons why values such as 1.3 ATA, 1.5 ATA, 90% O₂, or 10 L/min cannot be interpreted in isolation.

Each of these numbers describes only one part of the system.

Oxygen concentration at the concentrator outlet is not automatically the FiO₂ in the lungs

If an oxygen concentrator declares a high O₂ concentration at its outlet, this does not automatically mean that the person is inhaling the same concentration into the alveoli.

The actual FiO₂ depends on the delivery method. A mask may seal more or less effectively, delivered oxygen may mix with ambient gas, the person’s minute ventilation may change, and the pressure environment alters additional physical parameters of the system. This is particularly important in low-pressure chambers, where lower oxygen concentrations and non-tight breathing interfaces can lead to substantial mixing between delivered oxygen and the surrounding gas.

A very important principle therefore applies:

O₂ concentration at the source ≠ automatically the user’s true FiO₂ ≠ automatically the biological dose.

Likewise, flow in L/min is not itself an oxygen dose.

This information territory will be explored in detail in a separate article dedicated to FiO₂, pressure, time, and delivery method.

Why pressure changes more than simply “the amount of air”

Increased absolute pressure has physical effects of its own.

According to Boyle’s law, as pressure increases, the volume of gas within a closed space decreases. This mechanism is clinically crucial, for example, in decompression sickness or gas embolism, where pressure directly influences the volume of gas bubbles.

According to Henry’s law, as the partial pressure of a gas increases, the amount of that gas that can physically dissolve in a liquid also increases. During hyperbaric oxygen therapy, a high PO₂ therefore markedly increases the amount of oxygen dissolved directly in plasma — independently of hemoglobin.

This is one of the most important differences compared with simply increasing SpO₂.

In a healthy person under normal conditions, hemoglobin is already largely saturated. Increasing O₂ partial pressure therefore cannot continue indefinitely adding more oxygen to hemoglobin. An increasingly important contribution comes from the physically dissolved fraction of O₂ in plasma, which rises far more substantially at clinical hyperbaric pressures than during mild pressure exposure.

The same ATA does not mean the same oxygen exposure

Imagine two chambers set to exactly the same pressure.

In one, the person breathes ordinary air.

In the other, the person breathes a high concentration of oxygen through a tight-fitting interface.

The chamber pressure is the same. The oxygen exposure is not.

The reverse is also true. Two people may receive a similar oxygen concentration, but one at 1 ATA and the other at 2 ATA. These exposures are not equivalent either.

TANVEA will therefore progressively work with the framework:

FiO₂ × PRESSURE × TIME × DELIVERY

and, for medical questions, additionally with:

PURPOSE × PATIENT × PROTOCOL.

The name of the device or a single number on a display is simply not enough.

Why results from medical HBOT cannot be transferred to mild hyperbaric exposure

This is the most important editorial and scientific boundary of the entire article.

Medical hyperbaric oxygen therapy has established clinical protocols and professional indications for selected conditions. These include, among others, decompression sickness, carbon monoxide poisoning, selected problematic wounds, delayed radiation injury, refractory osteomyelitis, compromised grafts and flaps, sudden sensorineural hearing loss, and avascular necrosis.

These outcomes, however, were generated under specific medical protocols.

If a study uses 2.0 or 2.4 ATA, nearly 100% medical O₂, a defined duration, and a series of repeated exposures, the result cannot simply be renamed as evidence for the effect of a chamber operating at 1.3 ATA with a different oxygen concentration.

Current reviews emphasize that mild and traditional hyperbaric oxygenation have different physiology and clinical use, and that mild hyperbaric oxygenation remains substantially less studied for many medical applications.

Biological plausibility is not equivalent to clinical evidence.

This principle will apply to every future diagnosis-focused article within TANVEA Oxygen Systems™.

Mild pressure is not biologically “nothing” either

The opposite extreme would be equally inaccurate: claiming that everything below conventional medical HBOT is physiologically meaningless.

An increase in ambient pressure alone changes gas partial pressures and the mechanical conditions experienced by the body. If the concentration of inhaled O₂ also changes, the resulting oxygen exposure changes further.

Research on mild hyperbaric oxygenation describes potential changes in peripheral microcirculation, autonomic regulation, and metabolism, but contemporary reviews also emphasize that this field has not been investigated to a degree comparable with traditional HBOT and that the same clinical uses cannot automatically be inferred.

For TANVEA, the correct position therefore lies between two extremes:

mild hyperbaric exposure is not medical HBOT, but neither is it physically identical to remaining at normal atmospheric pressure.

What biologically follows from that difference must be evaluated mechanism by mechanism and outcome by outcome.

Hyperoxia is not automatically an advantage

A higher oxygen partial pressure can, in specific circumstances, be therapeutically extremely useful. That does not mean that the greater the oxygen exposure, the better the biological outcome.

Hyperoxia alters the cellular redox environment and may increase the formation of reactive oxygen species. Within a properly designed medical protocol, these changes are part of some of the signaling mechanisms associated with HBOT, but excessive exposure creates a risk of oxygen toxicity. This can include pulmonary manifestations and, at high hyperbaric doses, central nervous system toxicity including seizures.

Modern medicine therefore uses controlled oxygen administration even in normobaric settings, rather than a philosophy of “maximum O₂ for everyone.”

This provides the foundation for a separate future Oxygen Systems™ article:

Can there be too much oxygen? Hyperoxia, ROS, and why dose matters.

Hyperbaric safety is not a minor detail of technical design

A hyperbaric environment adds pressure physics and specific technical risks to oxygen physiology.

Changes in pressure can, under certain circumstances, lead to barotrauma of the ear, sinuses, or other gas-filled spaces. In environments with high oxygen concentrations, the importance of fire safety, material control, electrostatic management, grounding, maintenance, and correct device operation increases substantially.

The FDA issued a dedicated safety communication in August 2025 following reports of serious injuries and deaths associated with hyperbaric devices. It emphasized adherence to manufacturer instructions, fire-safety procedures, appropriate grounding, suitable materials, staff training, patient monitoring, and regular maintenance.

Contemporary hyperbaric reviews likewise warn that severe fire or explosive events represent a potential risk not only in conventional hyperbaric systems but also in mild-pressure systems, and that safety standards must never be treated as optional.

For TANVEA, safety is therefore not a separate marketing parameter placed alongside pressure and performance. It is part of the definition of a high-quality hyperbaric exposure.

Where TANVEA Oxygen Systems™ fit within this framework

TANVEA Oxygen Systems™ are not intended to blur the boundary between wellness and medicine. They are intended to make that boundary easier to understand.

If a person has a diagnosed condition for which medical HBOT is indicated, the decision about treatment belongs in a medical setting and with an appropriately qualified healthcare professional.

If the context is TANVEA Experience Space™ and non-medical use of a low-pressure hyperbaric environment, the more accurate term is mild hyperbaric exposure. This does not mean that pressure or oxygen have no physiological effects. It means that we will not present the exposure as clinical HBOT or automatically transfer clinical outcomes obtained under different pressures, FiO₂ levels, and protocols.

This distinction creates room for a much better question.

Not:

“Does a hyperbaric chamber work?”

but:

“What pressure was the person exposed to, what oxygen concentration did they actually breathe, how was the oxygen delivered, how long did the exposure last, what was its purpose, and what evidence supports the expected outcome under those specific conditions?”

That is the question on which a true Oxygen System can be built.

Key message

Oxygen therapy, medical hyperbaric oxygen therapy, and mild hyperbaric exposure are not three marketing names for the same technology.

Normobaric oxygen therapy increases oxygen concentration at approximately normal atmospheric pressure.

Medical HBOT combines a high partial pressure of medical oxygen with increased ambient pressure within a precisely defined clinical protocol.

Mild hyperbaric exposure uses lower pressure, and its true oxygen dose depends on which gas the person is breathing and how that gas is delivered.

All three situations can, under certain conditions, increase oxygen availability compared with breathing ordinary air. But not to the same extent, through the same mechanism, or with the same evidence base.

For TANVEA Oxygen Systems™, the decisive question is therefore not:

How much oxygen does the device produce?

Nor:

What is the maximum pressure the chamber can reach?

But:

What real oxygen exposure is created by the combination of FiO₂, pressure, time, and delivery method — and what does the available evidence actually support for that specific exposure?

That is the boundary between oxygen marketing and oxygen physiology.

---

FAQ

Is oxygen therapy the same as hyperbaric oxygen therapy?

No. Conventional medical oxygen therapy increases FiO₂ at approximately normal atmospheric pressure. During HBOT, a person breathes a high concentration of medical O₂ while exposed to increased ambient pressure.

Is exposure in a chamber at 1.3 ATA hyperbaric oxygen therapy?

It is hyperbaric exposure in the literal sense that the pressure is above 1 ATA, but it is not automatically equivalent to clinical HBOT. FiO₂, oxygen delivery method, exposure time, device design, and purpose also matter. Contemporary professional frameworks separate low-pressure exposures from standard clinical HBOT protocols.

Is 1.5 ATA twice normal atmospheric pressure?

No. 1 ATA represents approximately atmospheric pressure at sea level. 1.5 ATA is approximately 50% higher absolute pressure, not double.

Does 90% oxygen from a concentrator mean the person is breathing FiO₂ 0.90?

Not necessarily. Actual FiO₂ depends on the breathing interface, its seal, flow rate, the person’s ventilation, and mixing with ambient gas.

Is 10 L/min a greater “oxygen dose” than 5 L/min?

Flow alone is insufficient. It is only one variable. Without knowing O₂ concentration, pressure, delivery method, and the person’s ventilation, L/min cannot define the actual biological oxygen exposure.

Why does the amount of oxygen dissolved in plasma increase during HBOT?

Because, according to Henry’s law, increasing O₂ partial pressure increases the amount of oxygen physically dissolved in the liquid component of blood. At clinical hyperbaric pressures, this increase can be substantial.

Can results from a study at 2.4 ATA be transferred to a chamber operating at 1.3 ATA?

No. These are different physical and biological exposures. Different pressure, FiO₂, exposure time, or oxygen delivery method can substantially alter the resulting dose and physiological response.

Does mild hyperbaric exposure have no biological effect?

It is not accurate to describe it as a physically neutral environment. Increased pressure changes gas partial pressures, and if FiO₂ is also increased, oxygen exposure changes further. Clinical evidence from traditional HBOT, however, cannot automatically be transferred to this setting.

Is more oxygen always better?

No. Oxygen is essential for life and can be therapeutically crucial in medicine, but excessive hyperoxia can be biologically undesirable. Its effects depend on dose, duration, pressure, and the specific clinical or physiological context.

Is mild hyperbaric exposure a substitute for medical HBOT?

No. For conditions in which medical HBOT is indicated, low-pressure wellness exposure should not be used as an automatic substitute.

---

Safety and professional notice

The content of this article is intended for educational and informational purposes. It is not intended for diagnosis, treatment, or decisions about the suitability of medical oxygen therapy or hyperbaric oxygen therapy and does not replace individual assessment, examination, or advice from a qualified healthcare professional.

Medical oxygen therapy and medical HBOT are used within specific clinical indications and protocols. Results obtained with high-pressure HBOT using medical oxygen cannot automatically be transferred to low-pressure non-medical exposures.

Hyperbaric environments may be associated with pressure-related injury to the ears, sinuses, or other gas-filled spaces. Higher oxygen exposures may carry their own risks, including oxygen toxicity. Environments and devices using high concentrations of O₂ require exceptional fire, material, electrical, and operational safety. In 2025, the FDA warned about reports of serious injuries and deaths associated with hyperbaric devices and emphasized the importance of correct operation, qualified supervision, monitoring, and maintenance.

If you have lung, cardiovascular, ear, or sinus disease, have recently undergone surgery, are experiencing acute respiratory symptoms, are being treated for a medical condition, or are considering oxygen therapy for a medical reason, the suitability of hyperbaric or oxygen exposure should be assessed with a qualified healthcare professional.

TANVEA mild hyperbaric exposure in a non-medical context is not medical HBOT and does not replace medical oxygen therapy, diagnosis, treatment, or any other form of healthcare.

---

SCIENTIFIC SOURCES AND REFERENCES

Undersea & Hyperbaric Medical Society. Hyperbaric Oxygen Therapy Indications, 15th Edition — Definition of Hyperbaric Oxygen and its Safe Delivery. Current professional framework for clinical HBO₂, medical oxygen, pressure ranges, safety standards, and supported indications.

Johnson-Arbor K. Mild and Traditional Hyperbaric Oxygenation: Clinical Uses and Safety Considerations. Undersea & Hyperbaric Medicine. 2026;53(2):247–254. Current review directly comparing mild and traditional hyperbaric oxygenation, their physiological differences, evidence base, and safety considerations.

Morningstar M, Strauchman M. Hyperbaric Oxygen Therapy and Mild Hyperbaric Oxygen Therapy Are Not Synonymous: A Narrative Review. Medical Sciences. 2026;14(3):360. Review addressing differences in pressure, O₂ concentration, dissolved oxygen, and terminology between HBOT and mHBOT. The authors work in hyperbaric clinical practice, which should be considered when interpreting the paper.

U.S. Food and Drug Administration. Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices — Letter to Health Care Providers. 25 August 2025. Official safety communication addressing fire risk, serious injuries, the need for monitoring, qualified operation, and maintenance of hyperbaric devices.

British Thoracic Society. Guideline for oxygen use in adults in healthcare and emergency settings. Emphasizes controlled oxygen therapy according to target oxygenation rather than indiscriminate liberal administration of O₂.

Heyboer M, Santiago W. Side Effects of Hyperbaric Oxygen Therapy. Undersea & Hyperbaric Medicine. 2026;53(2):399–414. Current professional review of potential adverse effects of HBO₂ and the importance of risk–benefit assessment.

Sevc J, et al. New insights into the mechanisms and prevention of central nervous system oxygen toxicity: A prospective review. Current mechanistic review of hyperbaric hyperoxia, ROS, and central nervous system oxygen toxicity.

Camporesi EM, Bosco G. Mechanisms of action of hyperbaric oxygen therapy. Undersea & Hyperbaric Medicine. 2014;41(3):247–252. Foundational mechanistic source for the relationship between elevated O₂ partial pressure, pressure itself, Boyle’s law, ROS/RNS signaling, and the biological effects of HBO₂.

Hyperbaric Physics. StatPearls / NCBI Bookshelf. Reference source for Boyle’s law, Henry’s law, physically dissolved oxygen, and the fundamental physics of hyperbaric environments.

Blood gas analyses in hyperbaric and underwater environments: a systematic review. Journal of Applied Physiology. Systematic review of human data examining the relationship between pressure, FiO₂, and arterial PO₂ under hyperbaric conditions.